Among adults hospitalized with influenza, Tamiflu treatment on the day of hospital admission was associated with a reduced risk for disease progression.
Adult and pediatric patients who received 2023-2024 influenza vaccines exhibited reduced risk for influenza-associated encounters across care settings.
Patients colonized with AMR pathogens showed high risk for infection with the same pathogen for up to 2 years, indicating a time window for decolonization interventions.